Home » Newsletters » BioWorld Science

BioWorld Science

April 24, 2012

View Archived Issues

Ranbaxy discloses novel matrix metalloproteinase inhibitors

Abbott reflects on accomplishments of first quarter 2012

Pfizer prepares new voltage-gated potassium channel activators

New HCV NS5A inhibitors patented by Merck & Co.

New candidate AstraZeneca antibacterial is active in vivo

First phase II data presented on BMS-791325 in hepatitis C

New HCV NS5B conformational modulator set for clinical testing

Discovery of clinical-stage c-Met inhibitor described

Optimized human protein inhibits thrombosis and neointima formation in vein grafts

Biota and Nabi to form combined company

Novel beta-secretase inhibitors presented by Janssen

Scripps Research receives grant to develop new eye disease treatments

Phase II trial of first-in-class defensin mimetic meets objectives

EnVivo reports new phosphodiesterase 9A inhibitors

Auris Medical completes enrollment in AM-111 trial

Ezose Sciences and Hirosaki University enter glycomics partnership

Resverlogix reveals lead candidate's mechanism of action

Asubio begins phase II study in acute spinal cord injury

Seikagaku and Biotie terminate license agreement

Phase III Latuda trials meet endpoints

Phase I RK-023 study for eyelash hypotrichosis complete

DMC recommends continuation of pivotal ThermoDox study

Fourth phase III study of QVA-149 in COPD meets primary endpoint

RaQualia selects potential IBS treatment for further development

Novo Nordisk and Oxford University launch novel collaboration